Effects of systemic β-blocker therapy on the efficacy and safety of topical brimonidine and timolol11None of the clinical investigators or authors have a proprietary interest in the products discussed in this manuscript; Pamela Barnett, Amy Batoosingh, Kuankuan Chen, Robert David, MD, Marsha Harrold, and Amanda VanDenburgh are employees of Allergan, Inc.
-
Published:2000-06
Issue:6
Volume:107
Page:1171-1177
-
ISSN:0161-6420
-
Container-title:Ophthalmology
-
language:en
-
Short-container-title:Ophthalmology
Reference11 articles.
1. Effects of brimonidine on aqueous humor dynamics in human eyes;Toris;Arch Ophthalmol,1995
2. Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily;Katz;Am J Ophthalmol,1999
3. Gerber SL, Cantor LB, Brater DC. Systemic drug interactions with topical glaucoma medications [review]. Surv Ophthalmol 1990;35:205–18. Comment in: Surv Ophthalmol 1991;36:160.
4. Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension;Schuman;Surv Ophthalmol,1996
5. Schuman JS, Horwitz B, Choplin NT, et al. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter trial. Chronic Brimonidine Study Group. [see comments] Arch Ophthalmol 1997;115:847–52. Comment in: Arch Ophthalmol 1999;117:417–9.
Cited by
72 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献